1. Home
  2. |Insights
  3. |PODCAST: Common Misperceptions About Undoing a Prior Administration's Executive Actions — C&M's First 100 Days Series

PODCAST: Common Misperceptions About Undoing a Prior Administration's Executive Actions — C&M's First 100 Days Series

Client Alert | 1 min read | 12.12.16

In the latest podcast for Crowell & Moring’s “First 100 Days” series, Dan Wolff, chair of the firm’s Administrative Law & Regulatory Practice, and Tom Lorenzen, partner in the firm’s Environment & Natural Resources Group and former assistant chief with the DOJ’s Environment & Natural Resources Division, sit down with Jim Flood, chair of Crowell & Moring’s Government Affairs Group, to discuss the possibility of President-elect Trump’s administration repealing, replacing, or eliminating prior executive actions, regulatory actions, or other policies.

Common misperceptions that will be addressed in this 15 minute podcast:

  • A new president can easily strike all the regulations he or she does not like on day one.
  • Regulations promulgated pursuant to Executive Orders can be erased simply by revoking the Executive Order.
  • Congress can simply eliminate regulations under the Congressional Review Act and the new administration can start on a blank slate.
  • Regulations at various stages of finalization can easily be discarded.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Contacts

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....